http://medipana.com/news/news_viewer.asp?NewsNum=219029&MainKind=A&NewsKind=5&vCount=12&vKind=1

Once developed, they have great benefits in terms of system and prices. Many Korean companies are conducting clinical trials in the US and Europe.

Not only global pharmaceutical companies, but also Korean pharmaceutical companies are rushing into the rare disease market with high unmet demands. Due to the characteristics of ‘rare diseases,’ it is not easy to conduct clinical trials for them, but there are currently about 7000 known rare diseases around the world, and drugs are developed for less than 10% of them, about 400 rare diseases. Only about 200 drugs have been approved by the US FDA.

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

IR/PR

The oral medication for infantile spasms (IS) is in phase 2 clinical trialsin Korea and the US, and the IV medication for status epilepticus (SE) is in phase 1 clinical trials in the US. The company has established new pipelines, including Alzheimer’s Disease, and is set to embark on clinical trials (phase 2)… by expanding […]

Bio-Pharm Solutions

145, Gwanggyo-ro, Yeongtong-gu, Suwon,
Gyeonggi-do, 16229, Korea
6F, C Bldg, Advanced Institute of Convergence Technology

CONTACT

Tel: 82-31-888-9608
Fax: 82-31-888-9601

MORE

Careers: shkim@b-psol.com
Clinical Trials: hsshin@b-psol.com
Investor Inquiries: uklee@b-psol.com
BD Partnering: uklee@b-psol.com